Psilocybin for depression: all studies (page 35)

5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.

ACS Chemical Neuroscience February 1, 2023 Lindsay P. Cameron, Seona D Patel, Maxemiliano V. Vargas et al. 113 citations

Psychedelic compounds have displayed antidepressant potential in both humans and rodents. Despite their promise, psychedelics can induce undesired effects that pose safety concerns and limit their clinical scalability. The rational development of optimized psychedelic-related medicines will require a full mechanistic understanding of how these molecules produce therapeutic effects. While the...

DOI: 10.1021/acschemneuro.2c00718 Full text 5-ht2a receptor Depression Neuroplasticity Psilocybin +12

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.

EClinicalMedicine February 1, 2023 Robin von Rotz, Eva M Schindowski, Johannes Jungwirth et al. 345 citations

Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been shown to markedly decrease symptom severity in an open-label setting or when compared to a waiting list group. To date, to our knowledge, no other trial compared a single, moderate dose of psilocybin to a placebo condition. In this double-blind, randomised clinical trial, 52...

DOI: 10.1016/j.eclinm.2022.101809 Full text Depression Major depressive disorder Psychedelic-assisted therapy Magic mushrooms +8

Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.

EClinicalMedicine February 1, 2023 Robin von Rotz, Eva M Schindowski, Johannes Jungwirth et al. 8 citations correction

We wish to provide a correction of the colour representation of Fig. 2 in order to harmonise the colours representing the Psilocybin and the Placebo condition with the corresponding figure caption and with the colour codes from all other figures across the manuscript. Fig. 2 now depicts the Psilocybin condition in blue and the Placebo condition in yellow. The error occurred as a result of an...

DOI: 10.1016/j.eclinm.2023.101841 Full text Psilocybin Depression Correction Clinical trials +1

Therapeutic potential of psilocybin: a promising agent in treating major depressive disorder

AIDASCO Reviews January 17, 2023 Dragana Marković, Eleonora Čapelja 2 citations

Major depressive disorder (MDD), also known as clinical depression, is a serious mental disorder and ranks first among psychiatric disorders that dominate the global disease burden. Recently, it was found that psilocybin, active compound derived from psychotropic mushrooms, can relieve depression symptoms rapidly and sustained benefits for several months. Beside MDD, psilocybin can alleviate...

DOI: 10.59783/aire.2023.15 Psilocybin Major depressive disorder Anxiety Hallucinogen +2

On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression.

Med (New York, N.Y.) January 13, 2023 Natalie Gukasyan 12 citations

Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression1 suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.

DOI: 10.1016/j.medj.2022.12.003 Full text Psychedelic therapy Mental health treatment Depression research Clinical trials +1

Psychedelics for Patients With Cancer: A Comprehensive Literature Review

Annals of Pharmacotherapy January 12, 2023 C Michael White, Nissen Weisman, Joseph Dalo 18 citations

Objective: To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca. Study Selection and Data Extraction: Studies assessing patients with cancer receiving...

DOI: 10.1177/10600280221144055 LSD MDMA Depression Psilocybin +7

Magic Mushrooms

The Meducator 2023 Alam Mehrjerdi Zahra, Bhavana Soma 2 citations

Psilocybin is a naturally occurring compound present in numerous mushroom species characterised by its hallucinogenic and psychedelic effects. Although it has a negative reputation, psilocybin has demonstrated therapeutic potential for treating mental health disorders by allowing the brain to make new neural connections which help the neural pathways adapt and break out of certain cognitive...

DOI: 10.35493/medu.43.18 Psilocybin Anxiety Major depressive disorder Addiction +4

Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.

Psychopharmacology 2023 Juliet Meccia, Joëlle Lopez, Rosemary C. Bagot 14 citations

Interest in the therapeutic potential of serotonergic psychedelic compounds including psilocybin has surged in recent years. While human clinical research suggests psilocybin holds promise as a rapid and long-lasting antidepressant, little is known about how its acute mechanisms of action mediate enduring alterations in cognition and behavior. Human neuroimaging studies point to both acute and...

DOI: 10.1007/s00213-022-06297-0 Full text Depression Affect Cognition Medial prefrontal cortex +8

Is psilocybin an effective antidepressant and what is its Mechanism of action?

Cell Reports Medicine 2023 J. John Mann 7 citations

Goodwin et al.1 report a single 25 mg dose of psilocybin has an antidepressant effect short-term in medication-resistant depression. Unanswered questions include drug blood level as a guide to dose, psychedelic effects relationship to antidepressant benefit, and potential suicide risk of psilocybin.

DOI: 10.1016/j.xcrm.2022.100906 Psilocybin Treatment-resistant depression Psychedelics Mental health

Functional MRI markers for treatment-resistant depression: Insights and challenges.

Progress in Brain Research 2023 Vasileia Kotoula, Jennifer W. Evans, Claire Punturieri et al. 17 citations

Imaging studies of treatment-resistant depression (TRD) have examined brain activity, structure, and metabolite concentrations to identify critical areas of investigation in TRD as well as potential targets for treatment interventions. This chapter provides an overview of the main findings of studies using three imaging modalities: structural magnetic resonance imaging (MRI), functional MRI...

DOI: 10.1016/bs.pbr.2023.04.001 Full text Ketamine Psilocybin Treatment-resistant depression Electroconvulsive therapy +7